J Hirsh, JE Dalen, DR Anderson, L Poller, H … - Chest, 2001 - chestjournal.chestpubs.org The optimal therapeutic range for oral anticoagulant therapy was reviewed by the
Committee on Antithrombotic Therapy of the American College of Chest Physicians
and the National Heart, Lung, and Blood Institute in 1986, 1989, 1992, ... Cited by 1386 - Related articles - BL Direct - All 23 versions
TM Hyers, G Agnelli, RD Hull, TA Morris, M … - Chest, 2001 - chestjournal.chestpubs.org Antithrombotic regimens modify one or more of these abnormalities. These
regimens include drugs that inhibit blood coagulation, such as the various
heparins and heparinoids; warfarin; direct thrombin inhibitors; drugs that ... Cited by 1083 - Related articles - BL Direct - All 28 versions
- ►chestpubs.org MN Levine, G Raskob, RJ Beyth, C Kearon, … - Chest, 2004 - chestjournal.chestpubs.org This chapter about hemorrhagic complications of anticoagulant treatment is part
of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy:
Evidence Based Guidelines. Bleeding is the major complication of ... Cited by 1078 - Related articles - BL Direct - All 14 versions
- ►chestpubs.org J Ansell, J Hirsh, E Hylek, A Jacobson, M … - Chest, 2008 - chestjournal.chestpubs.org This article concerning the pharmacokinetics and pharmacodynamics of vitamin K
antagonists (VKAs) is part of the American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th Edition). It describes the ... Cited by 888 - Related articles - BL Direct - All 21 versions
- ►ahajournals.org J Hirsh, V Fuster, J Ansell, JL Halperin - Journal of the American College of Cardiology, 2003 - Elsevier Warfarin, a coumarin derivative, produces an anticoagulant effect by interfering
with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K
epoxide). Vitamin K is a cofactor for the carboxylation of glutamate ... Cited by 354 - Related articles - BL Direct - All 20 versions
JS Ginsberg - New England Journal of Medicine, 1996 - content.nejm.org Venous thromboembolism, which includes deep-vein thrombosis (usually involving
leg veins) and pulmonary embolism, is a common cause of death. Treatment of
affected patients reduces the incidence of fatal pulmonary embolism, but ... Cited by 299 - Related articles - All 5 versions
EM Hylek, H Heiman, SJ Skates, MA Sheehan … - Jama, 1998 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Context.— Warfarin is ... Cited by 277 - Related articles - BL Direct - All 7 versions
AM Heck, BA DeWitt, AL Lukes - American Journal of Health-System Pharmacy, 2000 - ASHP P HARM .D., is Pharmacy Practice Resident, Mission St. Joseph's Hos- pital,
Asheville, NC. A NITA L. L UKES , P HARM .D., CACP, is Clinical Specialist,
Department of Pharmacy Services, Wishard Memorial Hospital, Indianapolis. ... Cited by 217 - Related articles - BL Direct - All 8 versions
TM HYERS - American journal of respiratory and critical care …, 1999 - 171.66.122.149 Venous thromboembolism (VTE) is a complex vascular disease with a multifactorial
pathogenesis that results in two major clinical manifestations. The first and
more common manifestation is deep venous thrombosis (DVT), which usually ... Cited by 173 - Related articles - BL Direct - All 6 versions
- ►monitorinr.co.il [PDF] AM Holbrook, JA Pereira, R Labiris, H … - Archives of Internal Medicine, 2005 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 167 - Related articles - All 10 versions
